Budigalimab

Jochen Salfeld, AbbVie's VP of virology, discusses the evolving concept of 'cure' in medicine, emphasizing the need for innovative thinking and technology integration. AbbVie is exploring curative potential in HIV through a combination therapy involving two antibodies, aiming for a disease-free state without continuous treatment. Salfeld highlights the importance of cross-functional collaboration and the use of AI and machine learning in R&D, drawing parallels to AbbVie's successful hepatitis C cure, Mavyret.

Immunotherapy advancements in small cell lung cancer (SCLC) include durvalumab's approval for limited-stage SCLC based on ADRIATIC trial, showing improved survival and PFS. Tarlatamab-dlle, a BiTE, received FDA approval for extended-stage SCLC. ABBV-706, an ADC, demonstrated efficacy in phase 1 study, while GSK5764227 received breakthrough designation for relapsed SCLC.

Trishula Therapeutics reports positive Phase I results for TTX-030, an anti-CD39 antibody for first-line metastatic pancreatic cancer, showing 30% objective response rate, 7.5 months median progression-free survival, and 19.1 months median overall survival. A global Phase II trial, ELTIVATE, is now enrolling.

Trishula Therapeutics reported positive Phase 1 results for TTX-030, an anti-CD39 antibody, in first-line metastatic pancreatic cancer patients, with strong median overall survival and marked benefit in HLA-DQhigh patients. The trial evaluated TTX-030 in combination with gemcitabine/nab-paclitaxel, with or without budigalimab, showing a 30% objective response rate and 19.1 months median overall survival. The treatment was well-tolerated, leading to the ongoing Phase 2 ELTIVATE study.